Dr Reddy's Laboratories (Dr Reddy's Laboratories) EBITDA Margin % : 31.08% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Dr Reddy's Laboratories's EBITDA for the three months ended in Dec. 2023 was $269 Mil. Dr Reddy's Laboratories's Revenue for the three months ended in Dec. 2023 was $867 Mil. Therefore, Dr Reddy's Laboratories's EBITDA margin for the quarter that ended in Dec. 2023 was 31.08%.

Dr Reddy's Laboratories EBITDA Margin % Historical Data

The historical data trend for Dr Reddy's Laboratories's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories EBITDA Margin % Chart

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBITDA Margin %

Get a 7-Day Free Trial

23.09

18.03

21.18

21.03

30.27

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial															29.59	26.68	33.25	33.83	31.08

Competitive Comparison of Dr Reddy's Laboratories's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's EBITDA Margin % falls into.

Dr Reddy's Laboratories EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Dr Reddy's Laboratories's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	904.755	/	2988.811
	=	30.27 %

Dr Reddy's Laboratories's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	269.308	/	866.601
	=	31.08 %

Dr Reddy's Laboratories (NYSE:RDY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Dr Reddy's Laboratories EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » EBITDA Margin %

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.